The clinical trials to test the safety of the formulation will be conducted in the UK on a group of 46 women (one-third treated with a high-dose of antibodies, one-third with a with a low-dose of antibodies and one-third with a placebo).
The three monoclonal antibodies (C2F5, C2G12 and C4E10) developed by Polymun, an Austrian-based partner of the EMPRO Consortium, have shown therapeutic effects. For the clinical trials, the antibodies will be formulated in a gel as topically applied microbicides.
“The antibodies developed by Polymun are widely used by the scientific community for research and described in many publications. In addition their unique neutralization properties, consistent quality, high purity and absence of protein additives make them valuable tools in obtaining more reliable research results,” commented Charles Kelly, EMPRO Project Coordinator and Professor at King’s College London. “That’s why we have high hopes for the results of the phase one clinical trial and that it will prove the first step in the speedy development of an effective formulation.”
The antibodies have been designed to guide the immune system’s defences towards their target by:
- directly eliminating invading agents (e.g. in mucosal surfaces)
- neutralizing infectious agents by blocking essential steps in the infective process
- activation of sterilizing immune functions (e.g. via the complement system or cytotoxic cells).
Silvia Novembre | alfa
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Life Sciences
20.01.2017 | Physics and Astronomy
20.01.2017 | Materials Sciences